Dr Daniel Vorobiof speaks to ecancer about real-world evidence with the use of a specialised digital health platform. Initially, he explains the background and methodology of the study.
He explains that clinical trials participation is both crucial for medical advancement and an important treatment option, at times the only one, for oncological patients. However, only an estimate of 3% of cancer patients worldwide enrol into such trials.
Dr Vorobiof then explains the results of the study. He mentions that clinical trials participation is directly influenced by the information received by cancer patients and caregivers.
In the end, he talks about the impact of this study on the future of clinical trials. He reiterates that digital health platforms are an important source for patients clinical trial awareness.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.